(ANAB) AnaptysBio - Ratings and Ratios
Antibodies, Modulators
ANAB EPS (Earnings per Share)
ANAB Revenue
Description: ANAB AnaptysBio
AnaptysBio Inc (NASDAQ:ANAB) is a clinical-stage biotechnology company specializing in the development of immunology therapeutics. The companys product pipeline includes several promising antibody programs targeting various autoimmune and inflammatory diseases, such as Rosnilimab, ANB032, ANB033, ANB101, and Imsidolimab. Notably, Imsidolimab is in Phase 3 development for generalized pustular psoriasis, indicating a potentially near-term commercial opportunity.
With a strong research focus, AnaptysBio has established collaborations with major pharmaceutical companies, including GlaxoSmithKline, to advance its antibody programs through preclinical and clinical milestones. The companys expertise in developing novel antibody therapies has the potential to address significant unmet medical needs in immunology.
From a technical analysis perspective, ANABs stock price has shown volatility, with an Average True Range (ATR) of 1.51, representing a 6.49% daily price movement. The stock is currently trading above its 20-day and 50-day Simple Moving Averages (SMA), indicating a potential bullish trend. However, it is still below its 52-week high of $40.33, suggesting room for growth.
Combining technical and fundamental analysis, we can forecast that ANABs stock price may experience an upward trend if the companys clinical trials, particularly Imsidolimabs Phase 3 trial, yield positive results. With a market capitalization of $687.21M and a lack of earnings (P/E ratio is None), the stocks performance will likely be driven by news flow and clinical milestones. If we see significant progress in the companys pipeline, the stock price could potentially reach $30-$35 in the near term, representing a 29%-51% increase from the current price of $23.32.
ANAB Stock Overview
| Market Cap in USD | 630m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-01-26 |
ANAB Stock Ratings
| Growth Rating | -28.5% |
| Fundamental | 40.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -57.8% |
| Analyst Rating | 4.42 of 5 |
ANAB Dividends
Currently no dividends paidANAB Growth Ratios
| Growth Correlation 3m | -56.5% |
| Growth Correlation 12m | -3.7% |
| Growth Correlation 5y | -30.2% |
| CAGR 5y | -8.35% |
| CAGR/Max DD 3y | -0.12 |
| CAGR/Mean DD 3y | -0.25 |
| Sharpe Ratio 12m | -1.55 |
| Alpha | 0.20 |
| Beta | 0.657 |
| Volatility | 105.56% |
| Current Volume | 1363.8k |
| Average Volume 20d | 425.4k |
| Stop Loss | 18.4 (-5.2%) |
| Signal | -0.99 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-132.6m TTM) > 0 and > 6% of Revenue (6% = 7.39m TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -12.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 208.2% (prev 1073 %; Δ -864.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.38 (>3.0%) and CFO -127.7m > Net Income -132.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.8m) change vs 12m ago 5.32% (target <= -2.0% for YES) |
| Gross Margin 99.03% (prev 92.14%; Δ 6.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.30% (prev 7.13%; Δ 25.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.98 (EBITDA TTM -66.5m / Interest Expense TTM 70.5m) >= 6 (WARN >= 3) |
Altman Z'' -6.65
| (A) 0.76 = (Total Current Assets 291.9m - Total Current Liabilities 35.5m) / Total Assets 335.2m |
| (B) -2.50 = Retained Earnings (Balance) -837.3m / Total Assets 335.2m |
| warn (B) unusual magnitude: -2.50 — check mapping/units |
| (C) -0.18 = EBIT TTM -69.0m / Avg Total Assets 381.3m |
| (D) -2.20 = Book Value of Equity -837.3m / Total Liabilities 380.0m |
| Total Rating: -6.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.56
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -19.09% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 4.89 = -2.49 |
| 5. Debt/Ebitda -5.21 = -2.50 |
| 7. RoE -367.0% = -2.50 |
| 8. Rev. Trend 88.11% = 6.61 |
| 9. EPS Trend 8.89% = 0.44 |
What is the price of ANAB shares?
Over the past week, the price has changed by -12.34%, over one month by -3.10%, over three months by -18.83% and over the past year by -49.90%.
Is AnaptysBio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANAB is around 17.22 USD . This means that ANAB is currently overvalued and has a potential downside of -11.24%.
Is ANAB a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.5 | 134.5% |
| Analysts Target Price | 45.5 | 134.5% |
| ValueRay Target Price | 18.9 | -2.4% |
Last update: 2025-09-05 04:32
ANAB Fundamental Data Overview
CCE Cash And Equivalents = 265.7m USD (Cash And Short Term Investments, last quarter)
P/S = 5.117
P/B = 114.7281
Beta = -0.194
Revenue TTM = 123.2m USD
EBIT TTM = -69.0m USD
EBITDA TTM = -66.5m USD
Long Term Debt = 344.5m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 346.5m USD (Calculated: Short Term 2.00m + Long Term 344.5m)
Net Debt = 302.2m USD (from netDebt column, last quarter)
Enterprise Value = 711.0m USD (630.2m + Debt 346.5m - CCE 265.7m)
Interest Coverage Ratio = -0.98 (Ebit TTM -69.0m / Interest Expense TTM 70.5m)
FCF Yield = -19.09% (FCF TTM -135.7m / Enterprise Value 711.0m)
FCF Margin = -110.2% (FCF TTM -135.7m / Revenue TTM 123.2m)
Net Margin = -107.7% (Net Income TTM -132.6m / Revenue TTM 123.2m)
Gross Margin = 99.03% ((Revenue TTM 123.2m - Cost of Revenue TTM 1.20m) / Revenue TTM)
Tobins Q-Ratio = -0.85 (set to none) (Enterprise Value 711.0m / Book Value Of Equity -837.3m)
Interest Expense / Debt = 5.66% (Interest Expense 19.6m / Debt 346.5m)
Taxrate = 21.0% (US default)
NOPAT = -69.0m (EBIT -69.0m, no tax applied on loss)
Current Ratio = 8.22 (Total Current Assets 291.9m / Total Current Liabilities 35.5m)
Debt / Equity = 4.89 (Debt 346.5m / last Fiscal Year total Stockholder Equity 70.9m)
Debt / EBITDA = -5.21 (Net Debt 302.2m / EBITDA -66.5m)
Debt / FCF = -2.55 (Debt 346.5m / FCF TTM -135.7m)
Total Stockholder Equity = 36.1m (last 4 quarters mean)
RoA = -39.55% (Net Income -132.6m, Total Assets 335.2m )
RoE = -367.0% (Net Income TTM -132.6m / Total Stockholder Equity 36.1m)
RoCE = -18.12% (Ebit -69.0m / (Equity 36.1m + L.T.Debt 344.5m))
RoIC = -190.8% (set to none) (NOPAT -69.0m / Invested Capital 36.1m)
WACC = 7.03% (E(630.2m)/V(976.7m) * Re(8.43%)) + (D(346.5m)/V(976.7m) * Rd(5.66%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 30.30 | Cagr: 0.17%
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -135.7m)
EPS Correlation: 8.89 | EPS CAGR: -12.25% | SUE: 0.36 | # QB: False
Revenue Correlation: 88.11 | Revenue CAGR: 181.5%
Additional Sources for ANAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle